Researchers May Wish to Respond to Notice of Special Interest in Developing an NCORP CCDR Study
Posted: March 13, 2020
Researchers who are developing an NCI Community Oncology Research Program (NCORP) cancer care delivery research (CCDR) study may wish to respond to a recent NCI Notice of Special Interest on understanding and enhancing oral anticancer medication use, adherence, and health care delivery.
Notice Number: NOT-CA-20-026, Research on Oral Anticancer Agents in the Contexts of Utilization, Adherence, and Health Care Delivery, was released Feb. 21, 2020. The first available due date is May 25, 2020, and the expiration date is May 08, 2023.
The Notice invites research applications that:
- characterize the patient and provider factors influencing utilization of oral anticancer agents;
- identify structural, systemic, and psychosocial barriers to adherence; and/or
- develop models and strategies to improve safe and effective delivery of oral anticancer agents.
Research may be focused at the patient (pediatric, adolescent, young adult, and/or adult), patient-caregiver dyad, provider, health care team, and/or health care delivery system levels.
Research that merges expertise from diverse areas of science and clinical disciplines (e.g., pharmacy, nursing, oncology, primary care) or is focused on molecularly targeted agents is not required, but strongly encouraged. Addressing the needs of groups subject to disparities, such as the elderly or medically underserved, is an NCI priority.
For more information, use the link above.